ETF Holdings Breakdown of IDYA

Stock NameIdeaya Biosciences Inc
TickerIDYA(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS45166A1025
LEI549300ULW08F62IJML11

News associated with IDYA

Legal & General Group Plc Buys 6,064 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
Legal & General Group Plc boosted its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 7.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,442 shares of the company’s stock after buying an additional 6,064 […] - 2025-04-25 08:12:49
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $53.58 Consensus Target Price from Brokerages
IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the fifteen analysts that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the […] - 2025-04-23 05:32:56
JPMorgan Chase & Co. Acquires 194,913 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
JPMorgan Chase & Co. boosted its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 244.3% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 274,693 shares of the company’s stock after purchasing an additional 194,913 shares during the period. JPMorgan Chase & Co.’s holdings in IDEAYA Biosciences were worth […] - 2025-04-17 07:27:21
Geode Capital Management LLC Has $51.12 Million Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
Geode Capital Management LLC increased its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 2.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,988,681 shares of the company’s stock after purchasing an additional 43,226 shares during the […] - 2025-04-14 08:43:01
Wellington Management Group LLP Sells 2,321 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
Wellington Management Group LLP cut its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 5.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 39,790 shares of the company’s stock after selling 2,321 shares during the quarter. Wellington Management Group LLP’s […] - 2025-04-14 07:50:48
Norges Bank Purchases Shares of 520,810 IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
Norges Bank acquired a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) during the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 520,810 shares of the company’s stock, valued at approximately $13,385,000. Several other institutional investors and hedge funds have also added to or reduced their stakes in IDYA. UBS AM a […] - 2025-04-08 09:22:52
Orion Portfolio Solutions LLC Reduces Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
Orion Portfolio Solutions LLC reduced its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 39.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 17,769 shares of the company’s stock after selling 11,784 shares during the period. Orion Portfolio Solutions LLC’s holdings in IDEAYA Biosciences were worth $457,000 at the end of the […] - 2025-04-08 08:02:50
Vanguard Group Inc. Buys 282,936 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
Vanguard Group Inc. increased its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 5.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 5,078,084 shares of the company’s stock after purchasing an additional 282,936 shares during the quarter. Vanguard Group Inc. owned about 0.06% of IDEAYA Biosciences worth $130,507,000 […] - 2025-04-08 07:28:47
Mitsubishi UFJ Asset Management Co. Ltd. Sells 30,870 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
Mitsubishi UFJ Asset Management Co. Ltd. trimmed its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 81.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,856 shares of the company’s stock after selling 30,870 […] - 2025-04-04 08:19:12
Charles Schwab Investment Management Inc. Acquires 23,738 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
Charles Schwab Investment Management Inc. grew its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 3.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 712,811 shares of the company’s stock after purchasing an additional 23,738 shares during the period. Charles Schwab Investment […] - 2025-03-20 08:14:48
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by Daiwa Securities Group Inc.
Daiwa Securities Group Inc. lifted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 44.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,792 shares of the company’s stock after acquiring an additional 853 shares during the quarter. Daiwa Securities Group […] - 2025-03-18 07:43:16
AlphaQuest LLC Lowers Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
AlphaQuest LLC trimmed its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 77.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 7,661 shares of the company’s stock after selling 26,401 shares during the period. AlphaQuest LLC’s holdings in IDEAYA Biosciences were worth $197,000 at the end of the most recent […] - 2025-03-17 08:03:03
Victory Capital Management Inc. Buys 27,806 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
Victory Capital Management Inc. increased its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 8.9% in the 4th quarter, Holdings Channel reports. The firm owned 341,063 shares of the company’s stock after purchasing an additional 27,806 shares during the period. Victory Capital Management Inc.’s holdings in IDEAYA Biosciences were worth $8,765,000 as of […] - 2025-03-14 07:56:54
Assetmark Inc. Boosts Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
Assetmark Inc. lifted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 2.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 45,269 shares of the company’s stock after purchasing an additional 1,084 shares during the period. Assetmark Inc. owned about 0.05% of IDEAYA Biosciences worth […] - 2025-03-12 07:58:56
Oppenheimer Asset Management Inc. Trims Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
Oppenheimer Asset Management Inc. trimmed its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 28.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,676 shares of the company’s stock after selling 3,382 shares during the quarter. […] - 2025-03-07 08:45:00
IDEAYA Biosciences Partners With ATTMOS To Advance AI/ML-Driven Oncology Drug Discovery
(RTTNews) - IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced on Monday that it has entered into a research collaboration with ATTMOS to advance its physics-based computational small molecule discovery platform. This initiative aims to identify the - 2025-03-03 18:38:21
IDEAYA Biosciences (NASDAQ:IDYA) & Lipella Pharmaceuticals (NASDAQ:LIPO) Head to Head Review
Lipella Pharmaceuticals (NASDAQ:LIPO – Get Free Report) and IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability. Analyst Ratings This is a breakdown of […] - 2025-02-19 07:06:49
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $53.67 Average PT from Brokerages
IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) has earned an average rating of “Moderate Buy” from the sixteen analysts that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation, thirteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. […] - 2025-02-07 06:32:50
R Squared Ltd Purchases Shares of 1,350 IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
R Squared Ltd purchased a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 1,350 shares of the company’s stock, valued at approximately $35,000. Other hedge funds and other institutional investors have also bought and sold shares of the company. Allworth […] - 2025-02-04 08:44:58

IDYA institutional holdings

The following institutional investment holdings of IDYA have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 53,565USD 973,812
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 26,184USD 476,025 1.9%
2025-05-08 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 94,838USD 1,724,155
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 42,350USD 769,923
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 42,350USD 769,923 1.9%
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 266USD 4,836
Total =259,553 USD 4,718,674
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.